University of Patras
Επαγόμενα HLA-G+ T- ρυθμιστικά κύτταρα (iHLA-G+ Tregs) για τη θεραπεία της οξείας νόσου μοσχεύματος κατά ξενιστή (GVHD)
Abstract
dc:descriptionAllogeneic hematopoietic cell transplantation (allo-HCT) represents a potentially curative therapeutic approach for a broad range of hematological malignancies. Its effectiveness relies not only on the conditioning regimen but also on the graft-versus-leukemia (GVL) effect, which is primarily mediated by donor T cells that recognize and eliminate residual malignant cells. However, the alloreactivity of these same cells against recipient tissues can lead to graft-versus-host disease (GvHD), which remains one of the major complications of allo-HCT. Therefore, the development of therapeutic approaches that limit GvHD without compromising the beneficial antileukemic response remains an important therapeutic goal. Regulatory T cells (Tregs), owing to their ability to suppress excessive immune responses and maintain immune tolerance, have attracted considerable interest as a cellular therapeutic approach for the prevention and treatment of GvHD. However, their clinical application is limited by the low numbers of naturally occurring Tregs in peripheral blood, the lack of specific surface markers for their efficient isolation, and the potential loss of suppressive function and stability during ex vivo expansion. In this context, HLA-G, an immunoregulatory molecule with a key role in maternal-fetal immune tolerance, represents an attractive target for the generation of regulatory T cells. Previous studies demonstrated that pharmacological hypomethylation of activated T cells with decitabine induces de novo HLA-G expression, leading to the generation of HLA-G⁺ induced regulatory T cells (iG-Tregs) with immunosuppressive properties. In the present doctoral thesis, we investigated the generation and preclinical evaluation of iG-Tregs derived from peripheral blood (PB) and cord blood (CB) T lymphocytes. Exposure to decitabine significantly induced HLA-G expression and enabled the successful generation of iG-Tregs from both cellular sources, with distinct immunophenotypic characteristics. Functional evaluation demonstrated very low alloreactivity of PB-iG-Tregs in vitro. Furthermore, co-culture of PB-iG-Tregs with conventional T cells (Tconv) was associated with significantly reduced lysis of allogeneic target cells compared with Tconv alone. Their favorable safety profile was further supported in vivo in a GvHD model, where PB-iG-Treg administration resulted in significantly improved survival and absence of histopathological signs of GvHD, while their co-administration with Tconv delayed disease onset and reduced disease severity. We next investigated whether iG-Tregs retained antileukemic activity. Both PB- and CB-iG-Tregs exhibited increased cytotoxic activity against K562 leukemia cells in vitro compared with their respective Tconv counterparts, while the antileukemic activity of PB-iG-Tregs was further confirmed against primary acute myeloid leukemia (AML) blasts. In an in vivo leukemia model, iG-Tregs from both cellular sources combined effective antileukemic activity with a significant reduction in GvHD and a survival advantage, which was more pronounced in the CB-iG-Treg group. Finally, GMP validation runs confirmed the feasibility and reproducibility of manufacturing clinical-grade PB-iG-Tregs. Despite reduced cell viability following decitabine exposure, sufficient cell numbers were generated, with consistent HLA-G induction and low alloreactivity, while the final cell products met the predefined release criteria. Overall, the findings of this doctoral thesis provide preclinical evidence supporting the favorable safety profile and dual immunoregulatory and antileukemic activity of iG-Tregs. Together with the feasibility and reproducibility of their GMP manufacturing at clinical scale, these findings support the further clinical evaluation of iG-Tregs as a novel cellular therapeutic approach for GvHD prevention following allo-HCT.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Christofi, Panagiota
- Χριστοφή, Παναγιώτα
Subjects
dc:subject × 26- Αλλογενής μεταμόσχευση αιμοποιητικών κυττάρων
- Νόσος μοσχεύματος κατά ξενιστή
- Υιοθετούμενη κυτταρική ανοσοθεραπεία
- Φαρμακολογική υπομεθυλίωση
- Αντιλευχαιμική δράση
- Ορθή παρασκευαστική πρακτική (GMP)
- Τ-Ρυθμιστικά κύτταρα
- HLA-G
- Allogeneic hematopoietic cell transplantation
- Graft-versus-host disease
- Adoptive cellular immunotherapy
- Pharmacological hypomethylation
- Antileukemic activity
- Good manufacturing practice (GMP)
- Regulatory T cells
- Βιολογία
- Φυσικές Επιστήμες
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Αιματολογία
- Biological Sciences
- Natural Sciences
- Biology
- Clinical Medicine
- Medical and Health Sciences
- Hematology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/63060